Purpose: Opioid analgesics are commonly used to treat vaso-occlusive pain episodes in sickle cell disease (SCD), but comprehensive evidence characterizing opioid use in this patient population is limited. Our objective was to characterize opioid use patterns among SCD patients using a large nationwide database.
| INTRODUCTION
Sickle cell disease (SCD) is a hemoglobin disorder characterized by homozygous or compound heterozygous mutations in the beta-globin genes. 1 It affects approximately 100 000 individuals in the US and 25 million people worldwide. 2, 3 Vaso-occlusive crisis (VOC) is one of the signature manifestations in SCD and leads to frequent emergency department (ED) visits and hospital admissions, resulting in an estimated $2.4 billion in US health care costs annually. 4 Opioid analgesics are a mainstay of pharmacotherapy in treating pain episodes in SCD, 1 although doses and types of opiate medications vary greatly among SCD patients. 5 The evidence on the patterns of opioid use in this patient population is rather limited, and there is still controversy on the dose of opioids that SCD patients use in their daily life. 6, 7 Many believe that patients with SCD tend to use more opioids than many other chronic pain conditions, 7 whereas some studies showed a relatively low opioid dose used in this patient population in their daily life. 5, 8, 9 However, most of the previous studies were based on single institutions with relatively small sample sizes or based on a self-reported questionnaire or diary, 5, 8, 9 which may limit the generalizability of the results. There are no studies investigating the use of opioids in both pediatric and adult patients. Therefore, a comprehensive evaluation of opioid use patterns among SCD patients using a national database is warranted.
We found that the opioid doses used by the adult SCD patients were approximately 6-mg oral morphine equivalents (OME) in a single-institution cohort, and the doses of opioids were correlated with vaso-occlusive complications such as pain crisis and avascular necrosis (AVN). 5 In this study, we utilized a large nationwide medical/pharmacy claim database to confirm the previous findings and test our hypothe- 
| Patient population
We conducted a retrospective cohort study of patients who were identified as having SCD using a validated SCD-identifying algorithm. 10 In brief, if at least 1 claim with an International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic code for SCD from an acute care hospital encounter (see Supplemental Table 1 for codes) or 2 separate claims with ICD-9-CM SCD diagnostic codes that were at least 30 days apart were present, then the individual was preliminarily defined as having SCD. An additional
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KEY POINTS
• Only 40% of SCD patients were on opioid analgesics during a 12-month span;
• Majority of the patients with SCD used relatively low doses of opioids in their daily life, whereas a cluster of patients had much higher dosing requirements;
• High-dose opioid users tended to utilize health care more frequently;
• Vaso-occlusive complications such as VOC and AVN were associated with high-dose opioid use.
SCD-identifying algorithm (RuSH) was also applied to the cohort to further select probable SCD cases (Supplemental Table 2 Selection of patients for this analysis is summarized in a CONSORT diagram ( Figure 1 ).
ICD-9-CM codes (Supplemental Table 3 
| Opioid medication dose conversion and group categorization
Information on opioid medication doses were determined from pharmacy dispensing records and converted to OME based on the following ratio: 1 mg codeine = 0.13 mg OME, 1 mg hydrocodone = 1 mg OME, 1 mg hydromorphone = 5 mg OME, 1 mg methadone = 4.7 mg OME, 1 mg tramadol = 0.2 mg OME, 1 mg oxycodone = 1.5 mg OME, 1 mg tapentadol = 0.4 mg OME, 1 mg meperidine = 0.1 mg OME, 1 mg oxymorphone = 3 mg OME, 1 mg pentazocine = 0.37 mg OME, 1 mg propoxyphene = 0.08 mg OME, 1 mcg/h transdermal fentanyl = 3 mg OME/day, 1 mcg/h transdermal buprenorphine patch = 2.5 mg OME/day. Approximately 10% of the opioid prescriptions lacked detailed dosage information and were excluded from the OME calculation. Opioid users were categorized into non/low-dose users (≤24.5 mg OME daily in the adult population with SCD) and high-dose users (>24.5 mg OME daily in the adult population with SCD). The cutoff of 24.5 mg OME was based on the 75 th percentile of the average daily oral opioid dose.
| Statistical analysis
In the univariate analysis, the characteristics of SCD patients including age, gender, medication use, health care utilization, and medical history were compared between non/low-dose users and high-dose users Doses of opioid medications converted to OME are reported in Table 2 . The median daily dose among opioid users was 1.85 mg OME (IQR 0.62-10.68 mg). The dose of opioids was 0.54 mg OME per day in the age groups of 0 to 9 years old, and significantly higher years old had the highest opioid dose (6.03 mg OME per day). In the pediatric patients (0-17 years old) on opioid medications, the vast majority (87%) used 0 to 5 mg OME per day, and only 3% used more than 30 mg OME daily (Figure 2) . By contrast, 55% of the adult patients (18+ years old) used 0 to 5 mg OME per day, and 23% took more than 30 mg OME daily. The daily dose of 30 mg OME daily was used as the highest cutoff here because it was a commonly used dosage form for morphine. Hydrocodone-containing and oxycodonecontaining medications were among the most commonly used opioids in both pediatric and adult patients (Figure 3) , each accounting for approximately 30% of the total number of opioid prescriptions.
Codeine-containing medications were more frequently used in the pediatric population (27%) compared with adult population (4%). The usage of stronger opioid medications such as morphine, hydromorphone, methadone, and fentanyl was higher in the adult patients (27%) compared with the pediatric patients (16%).
Descriptive and clinical characteristics of adult patients (18 years and older) by non/low-dose use and high-dose average daily opioid use are reported in Supplementary Table 4 . Older age, hydroxyurea use, and NSAID use were more common among high-dose opioids users. Hospitalizations and ED visits were also more common among high-dose opioid users. High-dose opioid users experienced a greater FIGURE 3 Proportion of opioid prescriptions among SCD patients FIGURE 2 Frequency of opioid use in the SCD patients incidence of VOCs (P < 0.0001), acute chest syndrome (ACS) (P = 0.0211), AVN (P < 0.0001), and chronic heart failure (P = 0.0027).
In the multivariable logistic regression models, patients that were older, used hydroxyurea (OR 3.9, 95% CI 2.8-5.5), and used NSAIDs (OR 2.0, 95% CI 1.4-2.7) had significantly higher odds of high-dose opioid use ( 
| DISCUSSION
Our findings showed that 39.9% of patients used opioid medications during a 12-month period, and the median dose among opioid users was 1.85 mg OME per day. We also found wide variations of opioid use in this patient population. While most patients (87% in pediatric patients and 55% in adult patients) used less than 5 mg OME daily, a non-trivial number of patients used more than 30 mg OME daily (3% and 23% in pediatric and adult patients, respectively). High-dose opioid use was associated with older age, use of hydroxyurea or NSAIDs, and these patients tended to have a greater frequency of hospital admissions. History of AVN and occurrence of VOCs were also associated with high-dose opioid use.
Opioid analgesic medications are the main treatment options for acute and chronic pain caused by SCD, 12 although the literature on the patterns of opioid use in this patient population is rather limited. 5, 8, 13, 14 Most studies were based on a self-reported questionnaire or diary with relatively small numbers of patients, which may be subject to recall or selection bias. 15 In this study, an administrative medical and pharmacy claims database was utilized to identify a large number of subjects with SCD and pharmacy dispensing records were extracted to evaluate patterns of opioid use. There is a misconception that patients with SCD tend to use more opioids than other chronic pain syndromes. 7 Our results here showed that the majority of patients with SCD (60.1%) did not use opioids on a daily basis, either because some SCD patients had pain but did not require opioids or because not all SCD patients experience daily pain. Previous studies showed that SCD patients have self-reported pain in 17% to 55% of the observed days. [16] [17] [18] The calculated average daily opioid dose in this study was relatively low (less than 2 mg OME) among opioid users.
Although patients in this cohort were younger (median age 17 years old), the daily opioid dose was similar at 4 mg OME in the adult patients (18+ years). Another consideration is that the subjects included in our analysis were all enrollees of private or employer-based insurance plans, and they tend to have fewer complications and lower health care utilization compared with patients enrolled on publicly insured health plans. 19, 20 Another study on a cohort of mainly publicly insured adult patients with SCD indicated that the median dose of daily OME was 6 mg, 5 which is similar to our observation in this study and lower than the dose used to treat other pain syndromes, such as chronic non-cancer pain. 21, 22 On the high end of the opioid use spectrum, our results characterized a group of SCD patients (3% in 0-17 year old group and 23% in 18+ year old group) requiring more than 30 mg OME daily opioid use, and this is consistent with previous reports showing a cluster of high health care utilizers among SCD patients. 23, 24 When treating chronic and acute pain in these patients, high doses of opioids are probably warranted to achieve adequate pain control, and legitimate opioid use should not be denied due to the current national opioid phobia. Although opioid-related deaths or severe adverse events cannot be determined in this study, it has been shown that using high-doses of opioids to treat VOC in SCD patients is a relatively safe approach. 25 We identified several associations with opioid use in this study population that support the use of higher doses in patients with worse disease. Hydroxyurea is indicated for SCD patients with A stepwise multiple logistic regression was performed based on opioid dose category (non/low-dose users vs high-dose users). The covariates originally placed into the analysis were chronic heart failure, chronic renal disease, stroke, pulmonary hypertension, avascular necrosis, priapism, iron overload, vaso-occlusive crisis, acute chest syndrome, and acute renal disease. Acute renal injury, avascular necrosis, iron overload, and vasoocclusive crisis remained in the regression model after covariates with P > 0.20 were eliminated from the model. Chronic heart failure, chronic renal disease, stroke, pulmonary hypertension, priapism, and acute chest syndrome eliminated from the model in a stepwise manner. The model was adjusted for age and gender.
recurrent moderate-to-severe painful crises, 26 and its use was indeed associated with high-dose opioid use. VOCs are usually treated with a multimodal approach, which was manifested by the association between opioid use and NSAID use. The results here showed that compared with non/low-dose users, high-dose opioid users were associated with frequent hospital admissions which emphasizes the importance of setting up a day hospital dedicated to making prompt and adequate pain treatment available to SCD patients. Experience from other hospitals and our own institution has shown that a day hospital can be an effective approach to manage this cluster of high health care utilizers by improving timeliness of treatment, decreasing ED visits, and reducing hospital admission rates. 23, 27 Vaso-occlusion and hemolysis each have a distinctive pathophysiology contributing to some sub-phenotypes of SCD. 28 Pain crises and AVN are believed to be related to the vaso-occlusion mechanism, whereas hemolysis is associated with complications such as pulmonary hypertension, stroke, and priapism. 28 Our observation that high-dose opioid use was associated with vaso-occlusive complications (VOCs and AVN), but not hemolytic complications (pulmonary hypertension, stroke, and priapism) suggests that opioid use is related more with vaso-occlusion rather than hemolysis-related mechanism. AVN is a relatively prevalent complication among the SCD patients, 29 resulting in severe chronic pain and disability, and it negatively affects health-related quality of life. 30 Early interventions, such as referring for orthopedic surgery procedures and/or physical therapy, may be warranted to reduce the opioid requirement in SCD patients with AVN. High-dose opioid use was associated with ACS and chronic heart failure in univariate but not in multivariate analyses (supplemental   table 4 ). Exposure to high-dose morphine and its active metabolite, morphine-6-glucuronide, has been suggested to increase the risk of ACS in SCD patients, 31 which is consistent with our observation.
Opioid use has also been associated with adverse respiratory outcomes, 32, 33 but not heart failure in other patient populations. 34, 35 Both the prevalence and dose of opioids increased significantly from the 0 to 9 age group to the 10 to 19 year age group, implying that the vaso-occlusive pain increases during the second decade of life in the SCD patients. The prevalence of opioid use slowly declined with increasing age after reaching the peak at the 20 to 29 years group, especially in the age group of 50+ years old ( Table 1 ). The reduced opioid use prevalence observed in the older age groups might result from a survival effect: patients with no opioid use may have less severe disease and hence lower mortality rates. This is consistent with findings that the pain severity rate in patients with SCD declines after 30 years of age, and patients with frequent VOCs have higher mortality risk. 36 On the other hand, the median dose among opioid users increased between ages 0 and 29 years old, plateaued in the third and fourth decades, and then reached the highest levels in the 50+ year age group (Table 2) . This may be due to the higher likelihood of developing AVN, which increases with age and was associated with greater opioid use in this study. 37 Additionally, patients with high quality medical care may have improved access to opioid treatment to manage VOCs, and they in turn may have a longer life expectancy. As patients with SCD live a longer life into their 50s to 60s in average, sometimes even 80s with improvement in medical care, [38] [39] [40] [41] it is important to investigate alternative approaches for pain management to complement the pain treatment regimen. Non-opioid-based treatments including both pharmacological and non-pharmacological approaches are particularly important for the cluster of SCD patients who fail to respond to the opioid therapies. 19, 42 The difference in medication utilization between privately and publicly insured patients should be addressed in further studies. Despite these potential limitations, our analysis identified several associations with opioid use, and it is the first study characterizing patterns of opioid use in both pediatric and adult SCD patients using a large nationwide database.
| STUDY LIMITATIONS

| CONCLUSION
In summary, our results showed that on the whole, patients with SCD used a relatively low dose of opioids in their daily life, while a subset of patients had much higher opioid dose requirements. The high-dose opioid users were associated with vaso-occlusive complications, such as VOC and AVN, and tended to seek health care utilization more frequently. They may contribute to the vast majority of health care costs associated with SCD; therefore, it is important to optimize the pain management in this subset of patients to reduce the health care costs. Early interventions for potentially modifiable complications such as AVN may help decrease high-dose opioid use in this patient population.
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